摘要
目的研究多西紫杉醇3周方案治疗激素难治性前列腺癌的疗效、毒副反应。方法对HRPC患者进行3周方案化疗:多西紫杉醇75mg/m2(第一天),泼尼松5mg,口服bid,21d为一周期。反应严重的患者之后的给药剂量改为70mg/m2。观察患者的前列腺特异性抗原水平、病灶的变化、毒副反应。结果 12例患者经治疗后PSA均有下降,5例PSA下降>50%。治疗前后PSA中位数分别为28和18,两者比较有统计学差异。复查MRI中2例出现病灶减小。所有患者骨扫描未见新发灶,骨痛的患者中50%有不同程度缓解。主要的副反应为骨髓抑制。结论多西紫杉醇3周方案对于我国HRPC患者的疗效是肯定的,但毒副反应对化疗进程影响很大,本研究建议将不能耐受的患者药物剂量降为70mg/m2。
Objective To investigate the response and toxicity of docetaxel plus prednisone in the treatment of hormonerefractory prostate cancer（HRPC）. Methods 12 patients with HRPC received 75 mg/m2 docetaxel intravenously, and took 5 mg prednisone orally on continuous basis for 3 weeks. The PSA response rate, changes of soft tissue metastases, symptoms and toxicity were recorded. Results The PSA level decreased in all patients, and decreased more than 50% in 5 patients. The median of PSA level was 28 and 18 respectively before and after treatment, with significant difference. 2 patients with measurable soft tissue disease showed significant response on MRI. No patients showed new lesions on bone SPECT, and bone pain was relieved in 50% of the patients. The most common toxicity was myelosuppression. Conclusions 70 mg/m2 docetaxel for 3 weeks in combination with prednisone is safe and effective for Chinese patients with HRPC.
出处
《现代泌尿外科杂志》
CAS
2011年第6期505-507,共3页
Journal of Modern Urology
关键词
多西紫杉醇
泼尼松
激素难治性前列腺癌
化疗
docetaxel
prednisone
hormone-refractory prostate cancer
chemotherapy
